secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0000920148-26-000098
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q4 revenue $3.52B (+5.6% YoY), adj EPS $4.07 beat; guides FY26 adj EPS $17.55-18.25
--------------------------------------------------------------------------------

- Q4 revenue $3.52B (up 5.6% YoY, organic 3.8%); diluted EPS $1.98; adjusted EPS $4.07 vs $3.45.
- Full-year 2025 revenue $13.95B (+7.2% YoY); adj EPS $16.44 (+12.8% YoY); free cash flow $1.21B.
- 2026 guidance: revenue $14.61-14.79B (midpoint +5.4%), adj EPS $17.55-18.25 (midpoint +8.9%), FCF $1.24-1.36B.
- Diagnostics revenue $2.73B (+5.5%); adj op margin 15.4% (up 150 bps). Biopharma Central Labs grew 11.1%.
- Repurchased $450M stock in 2025; declared $0.72/share dividend payable Mar 12, 2026; signed 13 lab partnership deals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000098/0000920148-26-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000098/lh-20260217.htm
  HTML page:      https://secwatch.observer/filing/0000920148-26-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer